medicare semaglutide is expanding access to weight-loss GLP-1 medications. Starting July 1, eligible Medicare beneficiaries can receive GLP-1 prescriptions for obesity for $50 a month through a new federal pilot program, even without Wegovy covered by Medicare: Insurance

While every medical treatment has potential side effects, non-invasive GLP-1 therapy generally carries a significantly lower risk profile than major abdominal surgery

These findings highlight the substantial weight-lowering effect of retatrutide, even in a relatively short treatment period and in people with T2D

It goes deeper than the surface, supporting the systems that hold skin

By inhibiting glucagon production, GLP-1 receptor agonists help maintain lower blood glucose levels, preventing unwanted spikes

IV therapy can be beneficial for providing immediate energy or hydration, while promoting vitality and serving as preventative care